{"id":"https://openalex.org/W4390116508","doi":"https://doi.org/10.1016/j.msard.2023.105400","title":"Neutropenia following immune-depletion, notably CD20 targeting, therapies in multiple sclerosis","display_name":"Neutropenia following immune-depletion, notably CD20 targeting, therapies in multiple sclerosis","publication_year":2023,"publication_date":"2023-12-22","ids":{"openalex":"https://openalex.org/W4390116508","doi":"https://doi.org/10.1016/j.msard.2023.105400","pmid":"https://pubmed.ncbi.nlm.nih.gov/38181696"},"language":"en","primary_location":{"id":"doi:10.1016/j.msard.2023.105400","doi":"https://doi.org/10.1016/j.msard.2023.105400","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.msard.2023.105400","pdf_url":"http://www.msard-journal.com/article/S2211034823008994/pdf","source":{"id":"https://openalex.org/S2764622253","display_name":"Multiple Sclerosis and Related Disorders","issn_l":"2211-0348","issn":["2211-0348","2211-0356"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Multiple Sclerosis and Related Disorders","raw_type":"journal-article"},"volume":null,"type":"review","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"http://www.msard-journal.com/article/S2211034823008994/pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5016912802","display_name":"David Baker","orcid":"https://orcid.org/0000-0002-8872-8711","observed_orcids":["https://orcid.org/0000-0002-8872-8711","https://orcid.org/0000-0001-7896-6217"]},"institutions":[{"id":"https://openalex.org/I166337079","display_name":"Queen Mary University of London","ror":"https://ror.org/026zzn846","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I166337079"]},{"id":"https://openalex.org/I4405263501","display_name":"Blizard Institute","ror":"https://ror.org/01y7pzx08","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I166337079","https://openalex.org/I4405263501"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"David Baker","raw_affiliation_strings":["Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, 4 Newark Street, London E1 2AT, United Kingdom. Electronic address: david.baker@qmul.ac.uk","Blizard Institute, Queen Mary University of London, United Kingdom"],"raw_orcid":"https://orcid.org/0000-0002-8872-8711","affiliations":[{"raw_affiliation_string":"Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, 4 Newark Street, London E1 2AT, United Kingdom. Electronic address: david.baker@qmul.ac.uk","institution_ids":["https://openalex.org/I166337079","https://openalex.org/I4405263501"]},{"raw_affiliation_string":"Blizard Institute, Queen Mary University of London, United Kingdom","institution_ids":["https://openalex.org/I166337079","https://openalex.org/I4405263501"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014158535","display_name":"Angray S. Kang","orcid":"https://orcid.org/0000-0002-4672-4114","observed_orcids":["https://orcid.org/0000-0002-4672-4114"]},"institutions":[{"id":"https://openalex.org/I166337079","display_name":"Queen Mary University of London","ror":"https://ror.org/026zzn846","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I166337079"]},{"id":"https://openalex.org/I4405263501","display_name":"Blizard Institute","ror":"https://ror.org/01y7pzx08","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I166337079","https://openalex.org/I4405263501"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Angray S. Kang","raw_affiliation_strings":["Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, 4 Newark Street, London E1 2AT, United Kingdom; Dental Institute, Queen Mary University of London, United Kingdom","Blizard Institute, Queen Mary University of London, United Kingdom","Dental Institute, Queen Mary University of London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, 4 Newark Street, London E1 2AT, United Kingdom; Dental Institute, Queen Mary University of London, United Kingdom","institution_ids":["https://openalex.org/I166337079","https://openalex.org/I4405263501"]},{"raw_affiliation_string":"Blizard Institute, Queen Mary University of London, United Kingdom","institution_ids":["https://openalex.org/I166337079","https://openalex.org/I4405263501"]},{"raw_affiliation_string":"Dental Institute, Queen Mary University of London, United Kingdom","institution_ids":["https://openalex.org/I166337079"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015754502","display_name":"Gavin Giovannoni","orcid":"https://orcid.org/0000-0001-9995-1700","observed_orcids":["https://orcid.org/0000-0001-9995-1700"]},"institutions":[{"id":"https://openalex.org/I166337079","display_name":"Queen Mary University of London","ror":"https://ror.org/026zzn846","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I166337079"]},{"id":"https://openalex.org/I225661044","display_name":"Barts Health NHS Trust","ror":"https://ror.org/00b31g692","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I225661044"]},{"id":"https://openalex.org/I2801259928","display_name":"Royal London Hospital","ror":"https://ror.org/019my5047","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I225661044","https://openalex.org/I2801259928"]},{"id":"https://openalex.org/I4405263501","display_name":"Blizard Institute","ror":"https://ror.org/01y7pzx08","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I166337079","https://openalex.org/I4405263501"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Gavin Giovannoni","raw_affiliation_strings":["Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, 4 Newark Street, London E1 2AT, United Kingdom; Clinical Board Medicine (Neuroscience), The Royal London Hospital London, BartsHealth NHS Trust, London, United Kingdom","Blizard Institute, Queen Mary University of London, United Kingdom","Clinical Board Medicine (Neuroscience), The Royal London Hospital London, BartsHealth NHS Trust, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, 4 Newark Street, London E1 2AT, United Kingdom; Clinical Board Medicine (Neuroscience), The Royal London Hospital London, BartsHealth NHS Trust, London, United Kingdom","institution_ids":["https://openalex.org/I166337079","https://openalex.org/I225661044","https://openalex.org/I2801259928","https://openalex.org/I4405263501"]},{"raw_affiliation_string":"Blizard Institute, Queen Mary University of London, United Kingdom","institution_ids":["https://openalex.org/I166337079","https://openalex.org/I4405263501"]},{"raw_affiliation_string":"Clinical Board Medicine (Neuroscience), The Royal London Hospital London, BartsHealth NHS Trust, London, United Kingdom","institution_ids":["https://openalex.org/I225661044","https://openalex.org/I2801259928"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5057445606","display_name":"Klaus Schmierer","orcid":"https://orcid.org/0000-0002-9293-8893","observed_orcids":["https://orcid.org/0000-0002-9293-8893"]},"institutions":[{"id":"https://openalex.org/I166337079","display_name":"Queen Mary University of London","ror":"https://ror.org/026zzn846","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I166337079"]},{"id":"https://openalex.org/I225661044","display_name":"Barts Health NHS Trust","ror":"https://ror.org/00b31g692","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I225661044"]},{"id":"https://openalex.org/I2801259928","display_name":"Royal London Hospital","ror":"https://ror.org/019my5047","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I225661044","https://openalex.org/I2801259928"]},{"id":"https://openalex.org/I4405263501","display_name":"Blizard Institute","ror":"https://ror.org/01y7pzx08","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I166337079","https://openalex.org/I4405263501"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Klaus Schmierer","raw_affiliation_strings":["Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, 4 Newark Street, London E1 2AT, United Kingdom; Clinical Board Medicine (Neuroscience), The Royal London Hospital London, BartsHealth NHS Trust, London, United Kingdom","Blizard Institute, Queen Mary University of London, United Kingdom","Clinical Board Medicine (Neuroscience), The Royal London Hospital London, BartsHealth NHS Trust, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, 4 Newark Street, London E1 2AT, United Kingdom; Clinical Board Medicine (Neuroscience), The Royal London Hospital London, BartsHealth NHS Trust, London, United Kingdom","institution_ids":["https://openalex.org/I166337079","https://openalex.org/I225661044","https://openalex.org/I2801259928","https://openalex.org/I4405263501"]},{"raw_affiliation_string":"Blizard Institute, Queen Mary University of London, United Kingdom","institution_ids":["https://openalex.org/I166337079","https://openalex.org/I4405263501"]},{"raw_affiliation_string":"Clinical Board Medicine (Neuroscience), The Royal London Hospital London, BartsHealth NHS Trust, London, United Kingdom","institution_ids":["https://openalex.org/I225661044","https://openalex.org/I2801259928"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5016912802"],"corresponding_institution_ids":["https://openalex.org/I166337079","https://openalex.org/I4405263501"],"apc_list":{"value":2830,"currency":"USD","value_usd":2830},"apc_paid":{"value":2830,"currency":"USD","value_usd":2830},"fwci":0.9061,"has_fulltext":true,"cited_by_count":20,"citation_normalized_percentile":{"value":0.69071816,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":96,"max":99},"biblio":{"volume":"82","issue":null,"first_page":"105400","last_page":"105400"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":0.986299991607666,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":0.986299991607666,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11725","display_name":"Immunodeficiency and Autoimmune Disorders","score":0.00139999995008111,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12919","display_name":"Blood disorders and treatments","score":0.0010000000474974513,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.996999979019165},{"id":"https://openalex.org/keywords/multiple-sclerosis","display_name":"multiple sclerosis","score":0.9829999804496765},{"id":"https://openalex.org/keywords/b-cell-depletion","display_name":"B-cell depletion","score":0.8560000061988831},{"id":"https://openalex.org/keywords/alemtuzumab","display_name":"alemtuzumab","score":0.9670000076293945},{"id":"https://openalex.org/keywords/cladribine","display_name":"cladribine","score":0.828000009059906},{"id":"https://openalex.org/keywords/ocrelizumab","display_name":"ocrelizumab","score":0.9079999923706055},{"id":"https://openalex.org/keywords/ofatumumab","display_name":"ofatumumab","score":0.9860000014305115},{"id":"https://openalex.org/keywords/ublituximab","display_name":"ublituximab","score":0.9449999928474426},{"id":"https://openalex.org/keywords/rituximab","display_name":"rituximab","score":0.9660000205039978},{"id":"https://openalex.org/keywords/hematopoietic-stem-cell-transplantation","display_name":"hematopoietic stem cell transplantation","score":0.8730000257492065},{"id":"https://openalex.org/keywords/granulopoiesis","display_name":"granulopoiesis","score":0.8019999861717224},{"id":"https://openalex.org/keywords/cytokine-deficiency","display_name":"cytokine deficiency","score":0.5640000104904175},{"id":"https://openalex.org/keywords/b-cell-recovery","display_name":"B cell recovery","score":0.5460000038146973}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8598147630691528},{"id":"https://openalex.org/C2779015954","wikidata":"https://www.wikidata.org/wiki/Q420164","display_name":"Alemtuzumab","level":3,"score":0.7972202897071838},{"id":"https://openalex.org/C2778714382","wikidata":"https://www.wikidata.org/wiki/Q410656","display_name":"Ofatumumab","level":4,"score":0.7056015729904175},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.6901236176490784},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.6282978057861328},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.5554211139678955},{"id":"https://openalex.org/C2779171977","wikidata":"https://www.wikidata.org/wiki/Q3151081","display_name":"Filgrastim","level":4,"score":0.545626163482666},{"id":"https://openalex.org/C2780640218","wikidata":"https://www.wikidata.org/wiki/Q8277","display_name":"Multiple sclerosis","level":2,"score":0.5413560271263123},{"id":"https://openalex.org/C2776036978","wikidata":"https://www.wikidata.org/wiki/Q425137","display_name":"Fingolimod","level":3,"score":0.5227335095405579},{"id":"https://openalex.org/C2781004633","wikidata":"https://www.wikidata.org/wiki/Q386119","display_name":"Natalizumab","level":3,"score":0.5023410320281982},{"id":"https://openalex.org/C18031839","wikidata":"https://www.wikidata.org/wiki/Q5009796","display_name":"CD20","level":3,"score":0.48744943737983704},{"id":"https://openalex.org/C2778384904","wikidata":"https://www.wikidata.org/wiki/Q21108353","display_name":"CD52","level":4,"score":0.48198240995407104},{"id":"https://openalex.org/C2778843634","wikidata":"https://www.wikidata.org/wiki/Q2013780","display_name":"Ocrelizumab","level":4,"score":0.44536393880844116},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.43327203392982483},{"id":"https://openalex.org/C147483822","wikidata":"https://www.wikidata.org/wiki/Q103537","display_name":"Antigen","level":2,"score":0.22999849915504456},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.20565569400787354},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.19511649012565613},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.18819749355316162},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.1751055121421814}],"mesh":[{"descriptor_ui":"D000069283","descriptor_name":"Rituximab","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000074323","descriptor_name":"Alemtuzumab","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007155","descriptor_name":"Immunologic Factors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D009103","descriptor_name":"Multiple Sclerosis","qualifier_ui":"Q000628","qualifier_name":"therapy","is_major_topic":true},{"descriptor_ui":"D009503","descriptor_name":"Neutropenia","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true},{"descriptor_ui":"D018951","descriptor_name":"Antigens, CD20","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1016/j.msard.2023.105400","doi":"https://doi.org/10.1016/j.msard.2023.105400","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.msard.2023.105400","pdf_url":"http://www.msard-journal.com/article/S2211034823008994/pdf","source":{"id":"https://openalex.org/S2764622253","display_name":"Multiple Sclerosis and Related Disorders","issn_l":"2211-0348","issn":["2211-0348","2211-0356"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Multiple Sclerosis and Related Disorders","raw_type":"journal-article"},{"id":"pmid:38181696","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/38181696","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Multiple sclerosis and related disorders","raw_type":"Journal Article"},{"id":"pmh:oai:qmro.qmul.ac.uk:123456789/93601","doi":null,"is_oa":false,"landing_page_url":"https://qmro.qmul.ac.uk/xmlui/handle/123456789/93601","pdf_url":null,"source":{"id":"https://openalex.org/S4306400530","display_name":"Queen Mary Research Online (Queen Mary University of London)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I166337079","host_organization_name":"Queen Mary University of London","host_organization_lineage":["https://openalex.org/I166337079"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Article"}],"best_oa_location":{"id":"doi:10.1016/j.msard.2023.105400","doi":"https://doi.org/10.1016/j.msard.2023.105400","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.msard.2023.105400","pdf_url":"http://www.msard-journal.com/article/S2211034823008994/pdf","source":{"id":"https://openalex.org/S2764622253","display_name":"Multiple Sclerosis and Related Disorders","issn_l":"2211-0348","issn":["2211-0348","2211-0356"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Multiple Sclerosis and Related Disorders","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4390116508.pdf","grobid_xml":"https://content.openalex.org/works/W4390116508.grobid-xml"},"referenced_works_count":79,"referenced_works":["https://openalex.org/W19101126","https://openalex.org/W21251934","https://openalex.org/W37609260","https://openalex.org/W1816536644","https://openalex.org/W1973501787","https://openalex.org/W1978873873","https://openalex.org/W1994521383","https://openalex.org/W2001271673","https://openalex.org/W2009491846","https://openalex.org/W2027781307","https://openalex.org/W2035612608","https://openalex.org/W2084056567","https://openalex.org/W2094372936","https://openalex.org/W2107741982","https://openalex.org/W2109108939","https://openalex.org/W2110663171","https://openalex.org/W2119119729","https://openalex.org/W2126336004","https://openalex.org/W2140639042","https://openalex.org/W2141369787","https://openalex.org/W2145019007","https://openalex.org/W2149134901","https://openalex.org/W2151572058","https://openalex.org/W2157539129","https://openalex.org/W2171318929","https://openalex.org/W2330963720","https://openalex.org/W2331674683","https://openalex.org/W2337395477","https://openalex.org/W2559715624","https://openalex.org/W2583774324","https://openalex.org/W2597052847","https://openalex.org/W2623932875","https://openalex.org/W2734796066","https://openalex.org/W2757801096","https://openalex.org/W2769378959","https://openalex.org/W2792366526","https://openalex.org/W2802596299","https://openalex.org/W2802967146","https://openalex.org/W2807882529","https://openalex.org/W2876959260","https://openalex.org/W2889280561","https://openalex.org/W2896014118","https://openalex.org/W2899140676","https://openalex.org/W2914053307","https://openalex.org/W2963174936","https://openalex.org/W2972221943","https://openalex.org/W2977883158","https://openalex.org/W2993886923","https://openalex.org/W3022089954","https://openalex.org/W3034725616","https://openalex.org/W3043294634","https://openalex.org/W3046952836","https://openalex.org/W3120882765","https://openalex.org/W3124139149","https://openalex.org/W3159017041","https://openalex.org/W3182459058","https://openalex.org/W3195559913","https://openalex.org/W3198774415","https://openalex.org/W3203803649","https://openalex.org/W3215369393","https://openalex.org/W4200037894","https://openalex.org/W4205681939","https://openalex.org/W4206320827","https://openalex.org/W4220842043","https://openalex.org/W4281690664","https://openalex.org/W4283784612","https://openalex.org/W4292550557","https://openalex.org/W4293105031","https://openalex.org/W4308180703","https://openalex.org/W4308308007","https://openalex.org/W4316670356","https://openalex.org/W4317936522","https://openalex.org/W4323980309","https://openalex.org/W4378214317","https://openalex.org/W4379967452","https://openalex.org/W4381486853","https://openalex.org/W4388848297","https://openalex.org/W4389411214","https://openalex.org/W6853447893"],"related_works":["https://openalex.org/W4409222728","https://openalex.org/W4292550557","https://openalex.org/W7164153872","https://openalex.org/W4400174733","https://openalex.org/W4404137626","https://openalex.org/W4411444885","https://openalex.org/W2809611711","https://openalex.org/W2757801096","https://openalex.org/W4413970836","https://openalex.org/W4381486853"],"abstract_inverted_index":{"Neutropenia":[0],"serves":[1],"as":[2],"a":[3,11],"risk":[4],"factor":[5,138],"for":[6,58,82,140],"severe":[7],"infection":[8],"and":[9,31,43,54,67,88,105,111,126,144],"is":[10,39],"consequence":[12],"of":[13,60,86,103,123],"some":[14,164],"immune-depleting":[15],"immunotherapies.":[16],"This":[17,94,150],"occurs":[18,96],"in":[19,26,100],"people":[20],"with":[21,163],"multiple":[22],"sclerosis":[23],"following":[24,49,91,136,147,158],"chemotherapy-conditioning":[25],"haematopoietic":[27],"stem":[28],"cell":[29,34,142,161],"transplantation":[30],"potent":[32],"B":[33,141,160],"targeting":[35],"agents.":[36],"Whilst":[37],"CD52":[38],"expressed":[40,74],"by":[41,75,117,128],"neutrophils":[42],"may":[44,114],"contribute":[45],"to":[46,98,132],"early-onset":[47],"neutropenia":[48,90,156],"alemtuzumab":[50],"treatment,":[51],"deoxycytidine":[52],"kinase":[53],"CD20":[55],"antigen":[56],"required":[57],"activity":[59],"cladribine":[61],"tablets,":[62],"off-label":[63],"rituximab,":[64],"ocrelizumab,":[65],"ofatumumab":[66],"ublituximab":[68],"are":[69,80,109],"not":[70],"or":[71],"only":[72],"weakly":[73],"neutrophils.":[76],"Therefore,":[77],"alternative":[78],"explanations":[79],"needed":[81],"the":[83,101,120,124,152],"rare":[84],"occurrence":[85],"early":[87],"late-onset":[89],"such":[92],"treatments.":[93,165],"probably":[95],"due":[97,131],"alterations":[99],"balance":[102],"granulopoiesis":[104],"neutrophil":[106],"removal.":[107],"Neutrophils":[108],"short-lived,":[110],"their":[112],"removal":[113],"be":[115],"influenced":[116],"drug-associated":[118],"infections,":[119],"killing":[121],"mechanisms":[122],"therapies":[125],"amplified":[127],"immune":[129],"dyscrasia":[130],"influences":[133],"on":[134],"neutropoiesis":[135],"growth":[137],"rerouting":[139],"recovery":[143],"cytokine":[145],"deficits":[146],"lymphocyte":[148],"depletion.":[149],"highlights":[151],"small":[153],"but":[154],"evident":[155],"risks":[157],"sustained":[159],"depletion":[162]},"counts_by_year":[{"year":2026,"cited_by_count":6},{"year":2025,"cited_by_count":11},{"year":2024,"cited_by_count":3}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2023-12-23T00:00:00"}